DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Vincristine (Vincristine) - Infection - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Infection (181)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Vincristine where reactions include infection. The selected reports were submitted to the FDA during the sample period of about a year.

 Reports 1 - 30 of 181   Next >>

Possible Vincristine side effects in 49 year old male

Reported by a physician from Norway on 2012-08-27

Patient: 49 year old male

Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Septic Shock, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Bleomycin Sulfate
    Dosage: 10000 iu, day 8 (2 escalated cycles)
    Indication: Hodgkin's Disease

Bleomycin Sulfate
    Dosage: 10000 iu, day 8 (4 standard cycles)

Cyclophosphamide
    Dosage: 650 mg/m2, day 1 (4 standard cycles)

Cyclophosphamide
    Dosage: 1250 mg/m2, day 1 (2 escalated cycles)
    Indication: Hodgkin's Disease

Doxorubicin HCL
    Dosage: 25 mg/m2, day 1 (4 standard cycles)

Doxorubicin HCL
    Dosage: 35 mg/m2, day 1 (2 escalated cycles)
    Indication: Hodgkin's Disease

Etoposide
    Dosage: 100 mg/m2, day 1-3 (4 standard cycles)

Etoposide
    Dosage: 200 mg/m2, day 1-3 (2 escalated cycles)
    Indication: Hodgkin's Disease

Prednisolone
    Dosage: 40 mg/m2, day 1-14 (4 standard cycles)
    Administration route: Oral

Prednisolone
    Dosage: 40 mg/m2, day 1-14 (2 escalated cycles)
    Administration route: Oral
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Dosage: 100 mg/m2, day 1-7 (2 escalated cycles)
    Administration route: Oral
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Dosage: 100 mg/m2, day 1-7 (4 standard cycles)
    Administration route: Oral

Vincristine
    Dosage: 1.4 mg/m2, day 8 (2 escalated cycles)
    Indication: Hodgkin's Disease

Vincristine
    Dosage: 1.4 mg/m2, day 8 (4 standard cycles)



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-27

Patient:

Reactions: Off Label Use, Gastrointestinal Toxicity, Neutropenia, Infection

Drug(s) suspected as cause:
Carboplatin
    Dosage: 6 courses in high risk
    Indication: Retinoblastoma

Cyclophosphamide
    Indication: Retinoblastoma

Doxorubicin Hydrochloride
    Dosage: 4 courses in intermediate risk and 6 courses in high risk
    Indication: Retinoblastoma

Etoposide
    Indication: Retinoblastoma

Vincristine
    Dosage: 4 courses in intermediate risk and 6 courses in high risk
    Indication: Retinoblastoma

Other drugs received by patient: Neupogen



Possible Vincristine side effects in 49 year old male

Reported by a physician from Norway on 2012-08-27

Patient: 49 year old male

Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Pyrexia, Lung Infiltration, Septic Shock, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Bleomycin Sulfate
    Dosage: on day 8
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: for escalated cycles on day 1
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: for standard cycles on day 1

Doxorubicin Hydrochloride
    Dosage: for escalated cycles on day 1
    Indication: Hodgkin's Disease

Doxorubicin Hydrochloride
    Dosage: on day 1,for standard cycles

Etoposide
    Dosage: for the escalated cycles on day 1 to 3

Etoposide
    Dosage: for the escalated cycles on day 1 to 3

Etoposide
    Dosage: for the standard cycles, day 1 to 3
    Indication: Hodgkin's Disease

Prednisolone
    Dosage: on day 1 to 14 every 21 day cycle treatment for 6 cycles
    Administration route: Oral
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Dosage: day 1 to 7
    Administration route: Oral
    Indication: Hodgkin's Disease

Vincristine
    Dosage: on day 8
    Indication: Hodgkin's Disease



Possible Vincristine side effects in 49 year old male

Reported by a physician from Norway on 2012-08-24

Patient: 49 year old male

Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Pyrexia, Lung Infiltration, Septic Shock, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Bleomycin Sulfate
    Dosage: on day 8
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: for escalated cycles on day 1
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: for standard cycles on day 1

Doxorubicin Hydrochloride
    Dosage: on day 1,for standard cycles

Doxorubicin Hydrochloride
    Dosage: for escalated cycles on day 1
    Indication: Hodgkin's Disease

Etoposide
    Dosage: for the escalated cycles on day 1 to 3

Etoposide
    Dosage: for the escalated cycles on day 1 to 3

Etoposide
    Dosage: for the standard cycles, day 1 to 3
    Indication: Hodgkin's Disease

Prednisolone
    Dosage: on day 1 to 14 every 21 day cycle treatment for 6 cycles
    Administration route: Oral
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Dosage: day 1 to 7
    Administration route: Oral
    Indication: Hodgkin's Disease

Vincristine
    Dosage: on day 8
    Indication: Hodgkin's Disease



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-22

Patient:

Reactions: Abdominal Pain, Thrombosis, Hyperkalaemia, Coagulopathy, Hypoglycaemia, Hypocalcaemia, Hypoxia, Hiccups, Alanine Aminotransferase Abnormal, Pneumonitis, Cough, Pain in Extremity, Hypotension, Hyperglycaemia, External Ear Pain, Haematotoxicity, Dehydration, Lower Gastrointestinal Haemorrhage, Hypofibrinogenaemia, Aspartate Aminotransferase Abnormal, Hypokalaemia, Blood Bilirubin Abnormal, Pleural Effusion, Decreased Appetite, Gamma-Glutamyltransferase Abnormal, Hyponatraemia, Hypercalcaemia, Hypophosphataemia, Diarrhoea, Hypoalbuminaemia, Hypertension, Infection

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Asparaginase
    Dosage: 2500 units/m2/dose as 4 weekly doses
    Indication: Acute Lymphocytic Leukaemia

Bortezomib
    Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: on day 1 for all patients and on days 8, 15, 22 for cns invlovment
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: 10 mg/m2/day divided in to 2 doses for 14 consecutive days
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin HCL
    Dosage: given over 15-30 minutes on day 1
    Indication: Acute Lymphocytic Leukaemia

Hydrocortisone
    Dosage: on days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Methotrexate Sodium
    Dosage: 1 dose on day 15 for no cns involvement and on days 8, 15, 22 for cns involvement
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Other drugs received by patient: Vancomycin; Posaconazole; Voriconazole; Levofloxacin



Possible Vincristine side effects in male

Reported by a physician from United States on 2012-08-22

Patient: male

Reactions: Rectal Haemorrhage, Constipation, Cardiac Disorder, Hospitalisation, Granulocytopenia, Inappropriate Antidiuretic Hormone Secretion, Thrombocytopenia, Cardiac Failure Congestive, Pneumonia, Anaemia, Pancytopenia, Atrial Fibrillation, Febrile Neutropenia, Syncope, Embolism, Sepsis, Dehydration, Asthenia, Mantle Cell Lymphoma Recurrent, Leukopenia, Deep Vein Thrombosis, Infection

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on day 1
    Indication: Mantle Cell Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1
    Indication: Mantle Cell Lymphoma

Leukine
    Dosage: on day 9-15; 250 mcg/m2/day
    Indication: Mantle Cell Lymphoma

Leukine
    Dosage: on day 9-15; 250 mcg/m2/day
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Indication: Mantle Cell Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: on day 15; as infusion
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: on day 15; as infusion
    Indication: Mantle Cell Lymphoma

Vincristine
    Dosage: on day 1 (maximum dose: 2mg)
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Dosage: on day 1 (maximum dose: 2mg)
    Indication: Mantle Cell Lymphoma



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-21

Patient:

Reactions: Off Label Use, Gastrointestinal Toxicity, Neutropenia, Infection

Drug(s) suspected as cause:
Carboplatin
    Dosage: 6 courses in high risk
    Indication: Retinoblastoma

Cyclophosphamide
    Indication: Retinoblastoma

Doxorubicin HCL
    Dosage: 4 courses in intermediate risk and 6 courses in high risk
    Indication: Retinoblastoma

Etoposide
    Indication: Retinoblastoma

Vincristine
    Dosage: 4 courses in intermediate risk and 6 courses in high risk
    Indication: Retinoblastoma

Other drugs received by patient: Neupogen



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-20

Patient:

Reactions: Abdominal Pain, Thrombosis, Hyperkalaemia, Hypoglycaemia, Coagulopathy, Hypokalaemia, Blood Bilirubin Abnormal, Hiccups, Pleural Effusion, Hypoxia, Hypocalcaemia, Alanine Aminotransferase Abnormal, Cough, Pneumonitis, Decreased Appetite, Pain in Extremity, Hypotension, Hyperglycaemia, Gamma-Glutamyltransferase Abnormal, Hyponatraemia, External Ear Pain, Hypercalcaemia, Haematotoxicity, Hypophosphataemia, Diarrhoea, Dehydration, Hypoalbuminaemia, Lower Gastrointestinal Haemorrhage, Hypertension, Hypofibrinogenaemia, Aspartate Aminotransferase Abnormal, Infection

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Asparaginase
    Dosage: 2500 units/m2/dose as 4 weekly doses
    Indication: Acute Lymphocytic Leukaemia

Bortezomib
    Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: on day 1 for all patients and on days 8, 15, 22 for cns invlovment
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: 10 mg/m2/day divided in to 2 doses for 14 consecutive days
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Dosage: given over 15-30 minutes on day 1
    Indication: Acute Lymphocytic Leukaemia

Hydrocortisone
    Dosage: on days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: 1 dose on day 15 for no cns involvement and on days 8, 15, 22 for cns involvement
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Other drugs received by patient: Levofloxacin; Voriconazole; Posaconazole; Vancomycin



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-14

Patient:

Reactions: Thrombosis, Abdominal Pain, Hyperkalaemia, Hypoglycaemia, Coagulopathy, Hypoxia, Hypocalcaemia, Hiccups, Alanine Aminotransferase Abnormal, Cough, Pneumonitis, Pain in Extremity, Hyperglycaemia, Hypotension, External Ear Pain, Haematotoxicity, Dehydration, Lower Gastrointestinal Haemorrhage, Hypofibrinogenaemia, Aspartate Aminotransferase Abnormal, Hypokalaemia, Neuropathy Peripheral, Blood Bilirubin Abnormal, Pleural Effusion, Decreased Appetite, Hyponatraemia, Gamma-Glutamyltransferase Abnormal, Hypercalcaemia, Hypophosphataemia, Diarrhoea, Hypoalbuminaemia, Hypertension, Infection

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Asparaginase
    Dosage: 2500 units/m2/dose as 4 weekly doses
    Indication: Acute Lymphocytic Leukaemia

Bortezomib
    Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: on day 1 for all patients and on days 8, 15, 22 for cns invlovment
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: 10 mg/m2/day divided in to 2 doses for 14 consecutive days
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Dosage: given over 15-30 minutes on day 1
    Indication: Acute Lymphocytic Leukaemia

Hydrocortisone
    Dosage: on days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: 1 dose on day 15 for no cns involvement and on days 8, 15, 22 for cns involvement
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Other drugs received by patient: Levofloxacin; Vancomycin; Posaconazole; Voriconazole



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from Denmark on 2012-08-14

Patient:

Reactions: Transplant Failure, Cardiac Failure, Myelodysplastic Syndrome, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Carmustine
    Indication: Mantle Cell Lymphoma

Cyclophosphamide
    Indication: Mantle Cell Lymphoma

Cytarabine
    Indication: Mantle Cell Lymphoma

Doxorubicin HCL
    Indication: Mantle Cell Lymphoma

Etoposide
    Indication: Mantle Cell Lymphoma

Mabthera
    Indication: Mantle Cell Lymphoma

Melphalan Hydrochloride
    Indication: Mantle Cell Lymphoma

Prednisolone
    Indication: Mantle Cell Lymphoma

Vincristine
    Indication: Mantle Cell Lymphoma



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from Canada on 2012-08-09

Patient:

Reactions: Dermatitis Allergic, Pneumonia, Angina Pectoris, Febrile Neutropenia, Cognitive Disorder, Hepatitis, Arrhythmia, Interstitial Lung Disease, Gastrointestinal Disorder, Progressive Multifocal Leukoencephalopathy, Cardiac Failure Congestive, Infection

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin Hydrochloride
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone TAB
    Indication: Diffuse Large B-Cell Lymphoma

Radiotherapy
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Indication: Diffuse Large B-Cell Lymphoma



Possible Vincristine side effects in

Reported by a physician from Denmark on 2012-08-06

Patient:

Reactions: Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Carmustine
    Dosage: on day 1; beam/c
    Indication: Mantle Cell Lymphoma

Cyclophosphamide
    Dosage: day 1; cycle 5; chop regimen
    Indication: Mantle Cell Lymphoma

Cyclophosphamide
    Dosage: day 1; cycle 1; chop regimen

Cyclophosphamide
    Dosage: day 2-5 in beac regimen

Cyclophosphamide
    Dosage: day 1; cycle 3; chop regimen

Cytarabine
    Dosage: 3 or 2 g/m2, four-3 hour infusions; cycle 4
    Indication: Mantle Cell Lymphoma

Cytarabine
    Dosage: 3 or 2 g/m2, four-3 hour infusions; cycle 2

Cytarabine
    Dosage: day 2-5 in beam or beac regimen

Cytarabine
    Dosage: 3 or 2 g/m2, four-3 hour infusions; cycle 6

Doxorubicin HCL
    Dosage: on day 1; cycle 3
    Indication: Mantle Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1; cycle 1

Doxorubicin HCL
    Dosage: on day 1; cycle 5

Etoposide
    Dosage: day 2- 5; beam/c regimen
    Indication: Mantle Cell Lymphoma

Melphalan Hydrochloride
    Dosage: on day 6; beam regimen
    Indication: Mantle Cell Lymphoma

Prednisolone
    Dosage: on day 1-5; cycle 1

Prednisolone
    Dosage: on day 1-5; cycle 3

Prednisolone
    Dosage: on day 1-5; cycle 5
    Indication: Mantle Cell Lymphoma

Rituximab
    Dosage: day 1 cycle 5

Rituximab
    Dosage: day1 cycle 6, also given on day 9 for in-vivo purging

Rituximab
    Dosage: day 1 from cycle 4
    Indication: Mantle Cell Lymphoma

Vincristine
    Dosage: on day 1 ; cycle 5

Vincristine
    Dosage: on day 1; cycle 1
    Indication: Mantle Cell Lymphoma

Vincristine
    Dosage: on day 1; cycle 3



Possible Vincristine side effects in male

Reported by a lawyer from United States on 2012-08-03

Patient: male

Reactions: Tinnitus, Femur Fracture, Osteomyelitis, Oral Cavity Fistula, Erythema, Erectile Dysfunction, Neurotoxicity, Hypoaesthesia Oral, Oedema Peripheral, Carpal Tunnel Syndrome, Radiculopathy, Intervertebral Disc Protrusion, Cellulitis, Gingival Bleeding, Pneumonia, Pain in Extremity, Anaemia, Encephalopathy, Otitis Externa, Nasal Septum Deviation, Abscess JAW, Paraesthesia, Osteosclerosis, Rhinitis Allergic, Osteonecrosis, Mental Disorder, Osteoporosis, Pain, Multiple Myeloma, Periodontitis, Overdose, Neuropathy Peripheral, Intervertebral Disc Degeneration, Depression, Injury, Gastrooesophageal Reflux Disease, Pain in JAW, Dyspnoea, Spondylolysis, Spondylolisthesis, Hepatitis Acute, Musculoskeletal Pain, Febrile Neutropenia, Osteolysis, Cognitive Disorder, Deformity, Amnesia, Osteoarthritis, Anxiety, Osteonecrosis of JAW, Heart Rate Increased, Infection

Drug(s) suspected as cause:
Aredia

Thalidomide
    Dosage: 50 mg, qd

Vincristine

Zometa
    Dosage: 4 mg, qmo

Other drugs received by patient: Clonazepam; Dexamethasone; Oxycontin; Tegretol; Neurontin



Possible Vincristine side effects in 76 year old

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-02

Patient: 76 year old

Reactions: Lung Disorder, Neutropenia, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin Hydrochloride
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone
    Dosage: daily for 5 days
    Indication: Diffuse Large B-Cell Lymphoma

Radiotherapy
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Indication: Diffuse Large B-Cell Lymphoma

Other drugs received by patient: Neupogen



Possible Vincristine side effects in

Reported by a physician from United Kingdom on 2012-08-01

Patient:

Reactions: Neutropenia, Infection

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1440 mg, unk
    Indication: Mantle Cell Lymphoma

Doxorubicin Hydrochloride
    Dosage: 96 mg, unk
    Indication: Mantle Cell Lymphoma

Prednisone
    Dosage: 100 mg, unk
    Indication: Mantle Cell Lymphoma

Prednisone
    Dosage: 80 unk, unk

Velcade
    Dosage: 3 mg, unk
    Indication: Mantle Cell Lymphoma
    Start date: 2011-01-27

Vincristine
    Indication: Mantle Cell Lymphoma

Other drugs received by patient: Sando K / 00031402 /



Possible Vincristine side effects in male

Reported by a physician from United States on 2012-07-27

Patient: male

Reactions: Tinnitus, Femur Fracture, Oral Cavity Fistula, Osteomyelitis, Erectile Dysfunction, Neurotoxicity, Hypoaesthesia Oral, Carpal Tunnel Syndrome, Radiculopathy, Intervertebral Disc Protrusion, Cellulitis, Gingival Bleeding, Pneumonia, Anaemia, Encephalopathy, Otitis Externa, Abscess JAW, Nasal Septum Deviation, Paraesthesia, Rhinitis Allergic, Osteosclerosis, Osteonecrosis, Mental Disorder, Osteoporosis, Pain, Multiple Myeloma, Periodontitis, Neuropathy Peripheral, Overdose, Intervertebral Disc Degeneration, Injury, Depression, Gastrooesophageal Reflux Disease, Pain in JAW, Spondylolysis, Hepatitis Acute, Spondylolisthesis, Febrile Neutropenia, Osteolysis, Cognitive Disorder, Amnesia, Deformity, Osteoarthritis, Anxiety, Osteonecrosis of JAW, Infection

Drug(s) suspected as cause:
Aredia

Thalidomide
    Dosage: 50 mg, qd

Vincristine

Zometa
    Dosage: 4 mg, qmo

Other drugs received by patient: Clonazepam; Neurontin; Oxycontin; Tegretol; Dexamethasone



Possible Vincristine side effects in

Reported by a physician from United Kingdom on 2012-07-25

Patient:

Reactions: Neutropenia, Infection

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1440 mg, unk
    Indication: Mantle Cell Lymphoma

Doxorubicin Hydrochloride
    Dosage: 96 mg, unk
    Indication: Mantle Cell Lymphoma

Prednisone
    Dosage: 80 unk, unk

Prednisone
    Dosage: 100 mg, unk
    Indication: Mantle Cell Lymphoma

Velcade
    Dosage: 3 mg, unk
    Indication: Mantle Cell Lymphoma
    Start date: 2011-01-27

Vincristine
    Indication: Mantle Cell Lymphoma

Other drugs received by patient: Sando K / 00031402 /



Possible Vincristine side effects in

Reported by a physician from United States on 2012-07-23

Patient:

Reactions: Drug Ineffective, B-Cell Lymphoma, Palmar-Plantar Erythrodysaesthesia Syndrome, Device Related Infection, Upper Respiratory Tract Infection, Nervous System Disorder, Adverse Event, Lymphoma, Diffuse Large B-Cell Lymphoma, Mucosal Infection, Lymphoma AIDS Related, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Lymphoma AIDS Related

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: Lymphoma AIDS Related

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphoma AIDS Related

Rituximab
    Indication: Lymphoma AIDS Related

Vincristine
    Dosage: not more than 2mg
    Indication: Lymphoma AIDS Related

Other drugs received by patient: Antiretroviral Medications; Neupogen; Quinolone; Unknown Medication; Neupogen; Unknown Medication; Pegfilgrastim



Possible Vincristine side effects in male

Reported by a lawyer from United States on 2012-07-20

Patient: male

Reactions: Femur Fracture, Tinnitus, Osteomyelitis, Oral Cavity Fistula, Erectile Dysfunction, Neurotoxicity, Hypoaesthesia Oral, Intervertebral Disc Protrusion, Cellulitis, Pneumonia, Anaemia, Otitis Externa, Abscess JAW, Nasal Septum Deviation, Paraesthesia, Osteonecrosis, Rhinitis Allergic, Mental Disorder, Pain, Multiple Myeloma, Periodontitis, Overdose, Neuropathy Peripheral, Intervertebral Disc Degeneration, Injury, Depression, Gastrooesophageal Reflux Disease, Pain in JAW, Spondylolysis, Spondylolisthesis, Hepatitis Acute, Febrile Neutropenia, Osteolysis, Deformity, Amnesia, Osteoarthritis, Osteonecrosis of JAW, Infection

Drug(s) suspected as cause:
Aredia

Thalidomide
    Dosage: 50 mg, qd

Vincristine

Zometa
    Dosage: 4 mg, qmo

Other drugs received by patient: Neurontin; Clonazepam; Oxycontin; Dexamethasone; Tegretol



Possible Vincristine side effects in

Reported by a physician from United Kingdom on 2012-07-19

Patient:

Reactions: Neutropenia, Infection

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1440 mg, unk
    Indication: Mantle Cell Lymphoma

Doxorubicin HCL
    Dosage: 96 mg, unk
    Indication: Mantle Cell Lymphoma

Prednisone
    Dosage: 100 mg, unk
    Indication: Mantle Cell Lymphoma

Prednisone
    Dosage: 80 unk, unk

Velcade
    Dosage: 3 mg, unk
    Indication: Mantle Cell Lymphoma
    Start date: 2011-01-27

Vincristine
    Indication: Mantle Cell Lymphoma

Other drugs received by patient: Sando K / 00031402 /



Possible Vincristine side effects in

Reported by a physician from Japan on 2012-07-17

Patient:

Reactions: Neuropathy Peripheral, Interstitial Lung Disease, Neutropenia, Infection

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Indication: B-Cell Lymphoma

Neupogen
    Indication: B-Cell Lymphoma

Prednisolone
    Indication: B-Cell Lymphoma

Rituxan
    Dosage: 6 doses-2 days prior to each cycle of chop
    Indication: B-Cell Lymphoma

Vincristine
    Indication: B-Cell Lymphoma



Possible Vincristine side effects in

Reported by a physician from United Kingdom on 2012-07-17

Patient:

Reactions: Abdominal Pain, Tachycardia, Skin Toxicity, Pyrexia, Fatigue, Neuropathy Peripheral, Hepatotoxicity, Adverse Event, Dizziness, Oedema, Hallucination, Vomiting, Nausea, Gastrointestinal Toxicity, Neutropenic Sepsis, Nephropathy Toxic, Hypotension, Condition Aggravated, Adult T-Cell Lymphoma / Leukaemia, Mucosal Inflammation, Lung Disorder, Infection, Infusion Related Reaction

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on day 1 of 21 day cycle, (cycle 1-5)
    Indication: Adult T-Cell Lymphoma / Leukaemia

Cytarabine
    Indication: Adult T-Cell Lymphoma / Leukaemia

Doxorubicin HCL
    Dosage: on day 1 of 21 day, (cycle 1-5)

Doxorubicin HCL
    Dosage: on day 1 of 21 day, (cycle 1-5)
    Indication: Adult T-Cell Lymphoma / Leukaemia

Hydrocortisone
    Indication: Adult T-Cell Lymphoma / Leukaemia

Methotrexate
    Indication: Adult T-Cell Lymphoma / Leukaemia

Prednisolone
    Dosage: on days 1-5 of 21 day cycle, (cycle 1-5)
    Administration route: Oral
    Indication: Adult T-Cell Lymphoma / Leukaemia

Radiotherapy
    Indication: Adult T-Cell Lymphoma / Leukaemia

Vincristine
    Dosage: (maximum 2 mg) on day 1 of 21 day cycle, (cycle 1-5)
    Indication: Adult T-Cell Lymphoma / Leukaemia

Zenapax
    Dosage: on days 7 and 14 on cycle 1 of 21 day cycle
    Indication: Adult T-Cell Lymphoma / Leukaemia

Other drugs received by patient: Acyclovir; Thiabendazole; Cotrim; Itraconazole



Possible Vincristine side effects in

Reported by a individual with unspecified qualification from Croatia (Local Name: Hrvatska) on 2012-07-13

Patient:

Reactions: Mucosal Inflammation, Multi-Organ Failure, Tumour Lysis Syndrome, Febrile Neutropenia, Infection

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Burkitt's Lymphoma

Cytarabine
    Indication: Burkitt's Lymphoma

Dexamethasone
    Indication: Burkitt's Lymphoma

Doxorubicin Hydrochloride
    Indication: Burkitt's Lymphoma

Etoposide
    Indication: Burkitt's Lymphoma

Ifosfamide
    Indication: Burkitt's Lymphoma

Mabthera
    Indication: Burkitt's Lymphoma

Methotrexate
    Indication: Burkitt's Lymphoma

Methylprednisolone
    Indication: Prophylaxis

Prednisone
    Indication: Burkitt's Lymphoma

Vincristine
    Indication: Burkitt's Lymphoma



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-07-13

Patient:

Reactions: Neuropathy Peripheral, Neutropenia, Infection, Infusion Related Reaction

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Dosage: 6-821 day cycles; n=28
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Dosage: 6-821 day cycles; n=28

Obinutuzumab
    Indication: B-Cell Lymphoma

Prednisone
    Indication: B-Cell Lymphoma

Vincristine
    Indication: B-Cell Lymphoma



Possible Vincristine side effects in

Reported by a physician from United Kingdom on 2012-07-10

Patient:

Reactions: Abdominal Pain, Skin Toxicity, Tachycardia, Pyrexia, Fatigue, Neuropathy Peripheral, Hepatotoxicity, Adverse Event, Oedema, Dizziness, Hallucination, Vomiting, Gastrointestinal Toxicity, Nausea, Neutropenic Sepsis, Nephropathy Toxic, Hypotension, Adult T-Cell Lymphoma / Leukaemia, Condition Aggravated, Mucosal Inflammation, Lung Disorder, Infection, Infusion Related Reaction

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on day 1 of 21 day cycle, (cycle 1-5)
    Indication: Adult T-Cell Lymphoma / Leukaemia

Cytarabine
    Indication: Adult T-Cell Lymphoma / Leukaemia

Doxorubicin HCL
    Dosage: on day 1 of 21 day, (cycle 1-5)
    Indication: Adult T-Cell Lymphoma / Leukaemia

Hydrocortisone
    Indication: Adult T-Cell Lymphoma / Leukaemia

Methotrexate
    Indication: Adult T-Cell Lymphoma / Leukaemia

Prednisolone
    Dosage: on days 1-5 of 21 day cycle, (cycle 1-5)
    Administration route: Oral
    Indication: Adult T-Cell Lymphoma / Leukaemia

Radiotherapy
    Indication: Adult T-Cell Lymphoma / Leukaemia

Vincristine
    Dosage: (maximum 2 mg) on day 1 of 21 day cycle, (cycle 1-5)
    Indication: Adult T-Cell Lymphoma / Leukaemia

Zenapax
    Dosage: on days 7 and 14 on cycle 1 of 21 day cycle
    Indication: Adult T-Cell Lymphoma / Leukaemia

Other drugs received by patient: Cotrim; Itraconazole; Thiabendazole; Acyclovir



Possible Vincristine side effects in

Reported by a physician from United States on 2012-07-05

Patient:

Reactions: Fatigue, Central Nervous System Haemorrhage, Erythema Multiforme, Dyspnoea, Stomatitis, Vomiting, Gastrointestinal Toxicity, Nausea, Condition Aggravated, Rash, Haematotoxicity, Pulmonary Haemorrhage, Tumour Lysis Syndrome, Diarrhoea, Respiratory Failure, Neurological Symptom, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: for 5 days in cycle 1
    Indication: Burkitt's Lymphoma

Cyclophosphamide
    Dosage: days 1-5 during cycle 3,5 and 7

Cyclophosphamide
    Dosage: for 5 days in cycle 1
    Indication: Burkitt's Leukaemia

Cyclophosphamide
    Dosage: days 1-5 during cycle 3,5 and 7

Cytarabine
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Cytarabine
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Dexamethasone Sodium Phosphate
    Dosage: on days 1-5 of cycle 2,4 and 6

Dexamethasone Sodium Phosphate
    Dosage: on days 1-5 of cycle 2,4 and 6

Dexamethasone Sodium Phosphate
    Dosage: on days 1-5 of cycle 3,5 and 7
    Indication: Burkitt's Leukaemia

Dexamethasone Sodium Phosphate
    Dosage: on days 1-5 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Doxorubicin HCL
    Dosage: on days 4 and 5 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Doxorubicin HCL
    Dosage: on days 4 and 5 of cycle 3,5 and 7
    Indication: Burkitt's Leukaemia

Etoposide
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Etoposide
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Ifosfamide
    Dosage: on days 1-5 in cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Ifosfamide
    Dosage: on days 1-5 in cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Methotrexate
    Dosage: on day 1 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Methotrexate
    Dosage: on day 1 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Methotrexate
    Dosage: on day 1 of cycle 3,5 and 7

Methotrexate
    Dosage: on day 1 of cycle 2,4 and 6

Prednisone
    Dosage: for 7 days in cycle 1
    Indication: Burkitt's Lymphoma

Prednisone
    Dosage: for 7 days in cycle 1
    Indication: Burkitt's Leukaemia

Rituximab
    Dosage: on day 8 from cycle 3 to 7

Rituximab
    Dosage: on day 8 from cycle 3 to 7

Rituximab
    Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
    Indication: Burkitt's Leukaemia

Rituximab
    Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
    Indication: Burkitt's Lymphoma

Vincristine
    Dosage: on day 1 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Vincristine
    Dosage: on day 1 of cycle 2,4 and 6

Vincristine
    Dosage: on day 1 of cycle 3,5 and 7

Vincristine
    Dosage: on day 1 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Other drugs received by patient: Filgrastim; Unknown Medication; Leucovorin Calcium



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from Japan on 2012-07-05

Patient:

Reactions: Neuropathy Peripheral, Interstitial Lung Disease, Neutropenia, Infection

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Indication: B-Cell Lymphoma

Neupogen
    Indication: B-Cell Lymphoma

Prednisolone
    Indication: B-Cell Lymphoma

Rituximab
    Dosage: 6 doses-2 days prior to each cycle of chop
    Indication: B-Cell Lymphoma

Vincristine
    Indication: B-Cell Lymphoma



Possible Vincristine side effects in male

Reported by a physician from United States on 2012-07-03

Patient: male

Reactions: Femur Fracture, Tinnitus, Osteomyelitis, Oral Cavity Fistula, Erectile Dysfunction, Neurotoxicity, Hypoaesthesia Oral, Pneumonia, Cellulitis, Anaemia, Otitis Externa, Nasal Septum Deviation, Paraesthesia, Osteonecrosis, Rhinitis Allergic, Mental Disorder, Pain, Multiple Myeloma, Periodontitis, Overdose, Neuropathy Peripheral, Intervertebral Disc Degeneration, Injury, Depression, Gastrooesophageal Reflux Disease, Pain in JAW, Spondylolisthesis, Hepatitis Acute, Febrile Neutropenia, Osteolysis, Deformity, Amnesia, Osteoarthritis, Osteonecrosis of JAW, Infection

Drug(s) suspected as cause:
Aredia

Thalidomide
    Dosage: 50 mg, qd

Vincristine

Zometa
    Dosage: 4 mg, qmo

Other drugs received by patient: Dexamethasone; Tegretol; Oxycontin; Clonazepam; Neurontin



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from China on 2012-07-02

Patient:

Reactions: Hypotension, Bone Marrow Failure, Rash, Diffuse Large B-Cell Lymphoma, Herpes Zoster, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Bortezomib
    Dosage: at day 8

Bortezomib
    Dosage: day 1 (12 hr before chemotherapy)
    Indication: Diffuse Large B-Cell Lymphoma

Carboplatin
    Indication: Diffuse Large B-Cell Lymphoma

Cisplatin
    Indication: Diffuse Large B-Cell Lymphoma

Cyclophosphamide
    Indication: Diffuse Large B-Cell Lymphoma

Cytarabine
    Indication: Diffuse Large B-Cell Lymphoma

Daunorubicin HCL
    Indication: Diffuse Large B-Cell Lymphoma

Dexamethasone
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin Hydrochloride
    Indication: Diffuse Large B-Cell Lymphoma

Etoposide
    Indication: Diffuse Large B-Cell Lymphoma

Ifosfamide
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Indication: Diffuse Large B-Cell Lymphoma



Possible Vincristine side effects in

Reported by a physician from United States on 2012-06-28

Patient:

Reactions: Fatigue, Central Nervous System Haemorrhage, Erythema Multiforme, Vomiting, Stomatitis, Dyspnoea, Gastrointestinal Toxicity, Nausea, Condition Aggravated, Rash, Haematotoxicity, Pulmonary Haemorrhage, Tumour Lysis Syndrome, Respiratory Failure, Diarrhoea, Neurological Symptom, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: days 1-5 during cycle 3,5 and 7

Cyclophosphamide
    Dosage: days 1-5 during cycle 3,5 and 7

Cyclophosphamide
    Dosage: for 5 days in cycle 1
    Indication: Burkitt's Leukaemia

Cyclophosphamide
    Dosage: for 5 days in cycle 1
    Indication: Burkitt's Lymphoma

Cytarabine
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Cytarabine
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Dexamethasone
    Dosage: on days 1-5 of cycle 2,4 and 6

Dexamethasone
    Dosage: on days 1-5 of cycle 2,4 and 6

Dexamethasone
    Dosage: on days 1-5 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Dexamethasone
    Dosage: on days 1-5 of cycle 3,5 and 7
    Indication: Burkitt's Leukaemia

Doxorubicin HCL
    Dosage: on days 4 and 5 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Doxorubicin HCL
    Dosage: on days 4 and 5 of cycle 3,5 and 7
    Indication: Burkitt's Leukaemia

Etoposide
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Etoposide
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Ifosfamide
    Dosage: on days 1-5 in cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Ifosfamide
    Dosage: on days 1-5 in cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Methotrexate
    Dosage: on day 1 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Methotrexate
    Dosage: on day 1 of cycle 2,4 and 6

Methotrexate
    Dosage: on day 1 of cycle 3,5 and 7

Methotrexate
    Dosage: on day 1 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Prednisone TAB
    Dosage: for 7 days in cycle 1
    Indication: Burkitt's Leukaemia

Prednisone TAB
    Dosage: for 7 days in cycle 1
    Indication: Burkitt's Lymphoma

Rituximab
    Dosage: on day 8 from cycle 3 to 7

Rituximab
    Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
    Indication: Burkitt's Leukaemia

Rituximab
    Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
    Indication: Burkitt's Lymphoma

Rituximab
    Dosage: on day 8 from cycle 3 to 7

Vincristine
    Dosage: on day 1 of cycle 2,4 and 6

Vincristine
    Dosage: on day 1 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Vincristine
    Dosage: on day 1 of cycle 3,5 and 7

Vincristine
    Dosage: on day 1 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Other drugs received by patient: Unknown Medication; Leucovorin Calcium; Filgrastim



 Page 1   Next >>

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014